Akkermansia Muciniphila and Weight Loss: What the Evidence Shows

What is Akkermansia muciniphila?

Akkermansia muciniphila lives in the mucus layer lining the colon, feeding on mucin — the glycoprotein your own gut cells secrete. It typically accounts for one to four per cent of a healthy adult gut: a minor resident by headcount, a significant one by function, in a niche almost no other species competes for.

That habit sounds destructive and is the opposite. As Akkermansia grazes the mucus layer it stimulates the cells beneath to produce more of it, and releases acetate and propionate that feed neighbouring butyrate producers. In animals the net effect is a thicker mucus layer and a tighter gut barrier — the same thread connecting gut microbiome diversity to body weight more broadly.

Does Akkermansia help you lose weight?

On current evidence, Akkermansia has not been shown to cause meaningful weight loss in humans, though it improved several metabolic markers in one small trial. That distinction matters, and most marketing collapses it.

The association side is strong: across many observational studies, people with obesity, untreated type 2 diabetes or hypertension carry less Akkermansia than lean, metabolically healthy people. The intervention side is thin — one randomised trial, designed to test safety and tolerability rather than weight loss.

What do the Akkermansia weight loss results actually show?

The 2019 human trial

The study everyone cites is Depommier and colleagues in Nature Medicine (2019). Forty overweight, insulin-resistant volunteers were enrolled and 32 completed three months, taking 10¹⁰ A. muciniphila cells daily — live or pasteurised — or placebo.

The pasteurised form performed best, producing three results that reached significance against placebo: insulin sensitivity improved 28.62 per cent (P = 0.002), circulating insulin fell 34.08 per cent (P = 0.006) and total cholesterol fell 8.68 per cent (P = 0.02).

Body weight is where honesty is required. The pasteurised group ended 2.27 kg lighter than placebo, fat mass down 1.37 kg — but both carried a P value near 0.09, above the conventional 0.05 threshold. The change went in the hoped-for direction, it was small, and it could plausibly have been chance. The authors called the study proof-of-concept and exploratory.

Outcome in the 2019 trial	Result vs placebo	Statistically significant?
Insulin sensitivity	+28.62%	Yes (P = 0.002)
Circulating insulin	−34.08%	Yes (P = 0.006)
Total cholesterol	−8.68%	Yes (P = 0.02)
Body weight	−2.27 kg	No (P = 0.091)
Fat mass	−1.37 kg	No (P = 0.092)
Safety and tolerability	Well tolerated	Primary endpoint met

The observational evidence

The best-known observational work is Dao and colleagues in Gut (2016), which followed 49 overweight and obese adults through six weeks of calorie restriction. At baseline, higher faecal Akkermansia was inversely related to fasting glucose, waist-to-hip ratio and fat-cell diameter, and those who started with more improved more on insulin sensitivity. Interesting — and observational. It cannot say which way the arrow points.

What has not been shown

The counterweight deserves equal billing. A 2019 study of 65 women with severe obesity found Akkermansia lower in severe than moderate obesity, yet not associated with glucose-handling markers — and its rise after gastric bypass did not track metabolic improvement.

Also unshown: any trial beyond three months, any trial in a general population, any head-to-head against ordinary prebiotic fibre. No study has tested SlimTide's finished formula, and anyone claiming otherwise is describing research that does not exist.

How does Akkermansia work in the gut?

Three mechanisms are proposed, each resting on different evidence. The first is gut-barrier integrity: in mice, Everard and colleagues showed in PNAS (2013) that A. muciniphila reversed several diet-induced metabolic disorders and restored a mucus layer thinned by a high-fat diet. A leakier barrier lets bacterial fragments into circulation, driving the inflammation linked to insulin resistance.

The second is cross-feeding: the acetate and propionate it releases become substrate for butyrate producers — the pathway described in our guide to short-chain fatty acids and fat loss, and the route by which gut fermentation influences GLP-1 and natural appetite control.

The third is the most instructive. Plovier and colleagues reported in Nature Medicine (2017) that heat-killed Akkermansia improved metabolism in obese mice at least as well as the live organism, with one membrane protein reproducing much of the effect. Hence the pasteurised arm in the human trial — and why "live cultures" is not automatically the better format here.

Can you increase Akkermansia with food?

Yes, to a modest and variable degree. Akkermansia eats mucin rather than fibre, so food does not feed it directly; it changes the environment that lets it thrive, mainly by supporting the mucus layer and the fermenters around it.

Dietary lever	Why it plausibly helps	Everyday version
Polyphenol-rich foods	The most-studied dietary association with higher Akkermansia	Berries, red grapes, green tea, cocoa, olive oil
Prebiotic fibre	Inulin-type fructans shift the community and raise SCFA output	Chicory, onion, garlic, leek, oats, legumes
Resistant starch	Feeds the butyrate producers that cross-feed with it	Cooked-and-cooled potato or rice; green banana
Less ultra-processed food	Fibre-poor, emulsifier-heavy diets thin the mucus layer in animals	Swap packaged snacks for whole-food ones
Fewer needless antibiotics	Broad-spectrum courses flatten the community for months	See antibiotics and weight gain

Note what is missing: a food that reliably raises Akkermansia to a target level on a schedule. No such food exists, responses vary enormously, and no target level is established.

How much Akkermansia is in a supplement?

Very few supplements contain Akkermansia muciniphila at all: it is a strict anaerobe that dies on contact with oxygen and is hard to grow at scale. A 2024 critical review in Probiotics and Antimicrobial Proteins catalogues those technological and safety challenges, which is why it only reached the market recently.

Where it does appear, the dose is given as a cell count or as milligrams of blend. The 2019 trial used ten billion cells daily of a single organism. SlimTide differs: each capsule carries a 36 mg probiotic blend of Bifidobacterium infantis, Clostridium butyricum and Akkermansia muciniphila, with 211 mg chicory root inulin and 100 mg potato resistant starch, once a day.

Two honest observations follow. A 36 mg blend split three ways is not the single-organism dose used in the trial, and the label states no cell count, so the two cannot be compared. Pairing strains with prebiotic fibre is mechanistically reasonable — introduced organisms need fuel — but reasonable is not tested.

Is Akkermansia safe to take?

In the one available trial, three months at ten billion cells a day was safe and well tolerated — the primary endpoint. That is reassuring as far as it goes: 32 people, twelve weeks. Long-term human safety data do not exist, so caution is sensible if you are immunocompromised, pregnant or nursing, or taking immunosuppressants.

The honest bottom line

Akkermansia muciniphila earns its scientific interest: the mechanism is coherent, the animal work is strong, and the single human trial moved real metabolic markers. But the weight result in that trial was not statistically significant, the trial was small and short, and a study in severe obesity found no metabolic link at all. Treat it as active research rather than a settled weight-loss tool, and be sceptical of any product that calls the 2019 findings proof of fat loss.

Frequently asked questions

Related reading

• Gut microbiome diversity and body weight
• Short-chain fatty acids and fat loss
• Antibiotics and weight gain